Raymond James Financial
AMRX icon

Raymond James Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Raymond James Financial’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.12M Buy
734,043
+35,983
+5% +$483K ﹤0.01% 2099
2025
Q4 		$8.8M Sell
698,060
-44,350
-6% -$507K ﹤0.01% 2082
2025
Q3 		$7.43M Buy
742,410
+28,078
+4% +$252K ﹤0.01% 2159
2025
Q2 		$5.78M Buy
714,332
+117,830
+20% +$888K ﹤0.01% 2273
2025
Q1 		$5M Buy
596,502
+224,506
+60% +$1.87M ﹤0.01% 2326
2024
Q4 		$2.95M Buy
+371,996
New +$3.12M ﹤0.01% 2688

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Raymond James Financial's AMRX Position: Q1 2026 in Review

Raymond James Financial increased its Amneal Pharmaceuticals (AMRX) stake by 5.2% in Q1 2026, buying an estimated $483K and bringing the position to 734,043 shares worth $9.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

Raymond James Financial first reported a position in AMRX in Q4 2024 and has held it in 6 quarters since. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Raymond James Financial held 734,043 shares of Amneal Pharmaceuticals worth $9.12M as of Q1 2026.
  • Raymond James Financial bought 35,983 Amneal Pharmaceuticals shares in Q1 2026, an estimated $483K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2099 holding.
  • Raymond James Financial first reported a position in Amneal Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.